Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Anesth Analg ; 98(5): 1224-31, table of contents, 2004 May.
Article in English | MEDLINE | ID: mdl-15105192

ABSTRACT

UNLABELLED: Cardiac surgery results in significant impairment of beta-adrenergic receptor (beta AR) function and is a cause of depressed myocardial function after surgery. We previously demonstrated that acute administration of beta AR blocker during cardiopulmonary bypass (CPB) in an animal model of coronary artery bypass grafting (CABG) surgery attenuates beta AR desensitization, whereas chronic oral beta-blockade therapy in patients undergoing CABG surgery does not prevent it. Therefore we hypothesized that acute administration of metoprolol during CABG surgery would prevent acute myocardial beta AR desensitization. A placebo-controlled initial phase (n = 72) was performed whereby patients were randomized to either metoprolol 10 mg or placebo immediately before CPB. Then a second dose-finding study was performed where patients received 20 mg (n = 20) or 30 mg (n = 20) of metoprolol. Hemodynamic monitoring, atrial membrane adenylyl cyclase activity, atrial beta AR density, and postoperative outcomes were measured. All groups showed similar decreases in isoproterenol-stimulated adenylyl cyclase activity (13%-24%). Cardiac output remained similar in all 4 groups throughout the intraoperative and postoperative period. In addition, patients receiving metoprolol 20 or 30 mg had less supraventricular arrhythmias 24 h postoperatively compared with patients receiving metoprolol 10 mg or placebo. Therefore, unlike our previous animal model of CABG surgery, metoprolol did not attenuate myocardial beta AR desensitization. IMPLICATIONS: We investigated whether IV metoprolol given during cardiac surgery attenuates myocardial beta-adrenergic receptor (beta AR) desensitization. Although metoprolol did not reduce beta AR desensitization, the incidence of supraventricular arrhythmias was reduced by 75% in patients receiving 20 mg or 30 mg metoprolol.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Cardiac Surgical Procedures , Coronary Artery Bypass , Metoprolol/therapeutic use , Receptors, Adrenergic, beta/drug effects , Receptors, Adrenergic, beta/physiology , Adenylyl Cyclases/metabolism , Adrenergic beta-Antagonists/administration & dosage , Aged , Cardiac Output/physiology , Cardiotonic Agents/administration & dosage , Cardiotonic Agents/therapeutic use , Dose-Response Relationship, Drug , Double-Blind Method , Endpoint Determination , Female , Heart/drug effects , Hemodynamics/drug effects , Hemodynamics/physiology , Humans , Injections, Intravenous , Intraoperative Period , Male , Metoprolol/administration & dosage , Middle Aged , Myocardium/enzymology , Myocardium/metabolism , Tachycardia, Supraventricular/physiopathology , Tachycardia, Supraventricular/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL
...